lobeline

Small moleculeexperimental

Lobeline is an alkaloid found in "Indian tobacco" (Lobelia inflata), "Devil's tobacco" (Lobelia tupa), "cardinal flower" (Lobelia cardinalis), "great lobelia" (Lobelia siphilitica), and Hippobroma longiflora. Additionally, it is also found in Lobelia Chinensis. In its pure form, it is a white amorphous powder which is freely soluble in water. Lobeline has been sold, in tablet form, for use as a smoking cessation aid, and may have application in the treatment of other drug addictions such as addiction to amphetamines, cocaine, or alcohol. Lobeline has multiple mechanisms of action, acting as a VMAT2 ligand, which stimulates dopamine release to a moderate extent when administered alone, but reduces the dopamine release caused by methamphetamine. It also inhibits the reuptake of dopamine and serotonin and acts as a mixed agonist-antagonist at nicotinic acetylcholine receptors to which it binds at the subunit interfaces of the extracellular domain. It is also an antagonist at μ-opioid receptors. It seems to be a P-glycoprotein inhibitor, according to at least one study. It has been hypothesized that P-glycoprotein inhibition reduces chemotherapeutic resistance in cancer, presumably affecting any substrates of P-gp. — NCATS

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2004 (NCT00100074)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1[C@H](C[C@H](O)C2=CC=CC=C2)CCC[C@@H]1CC(=O)C3=CC=CC=C3
Mol. weight
337.4553 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lobeline
  • lobeline
  • lobeline
  • lobeline
  • lobeline hcl
  • lobeline hcl

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00664703Phase 2Jul 1, 2008Ceptaris, National Institute of Mental Health (NIMH), University of Kentucky
NCT00439504Phase 1Feb 22, 2007National Institute on Drug Abuse (NIDA), University of California, San Francisco
NCT00519259Phase 1Feb 1, 2006National Institute on Drug Abuse (NIDA), University of California, San Francisco
NCT00100074Phase 1Sep 1, 2004National Institute on Drug Abuse (NIDA), University of California, San Francisco
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute on Drug Abuse (NIDA)Government3312004
University of California, San FranciscoAcademic/Hospital3012004
CeptarisFor profit1112008
National Institute of Mental Health (NIMH)Government1012008
University of KentuckyAcademic/Hospital1012008
5 organizations
Page 1 / 1